

Endothelial protective properties of short-chain peptides that mimic α -helix B of erythropoietin in experimental preeclampsia

Propiedades protectoras endoteliales de péptidos de cadena corta que imitan la α -hélice B de la eritropoyetina en la preeclampsia experimental

Ivan V. Golubev; Vladimir V. Gureev; Mikhail V. Korokin; Anastasia V. Gureeva; Adelaida V. Polyanskaya; Mikhail V. Pokrovskii; Galina A. Lazareva; Natalia A. Bystrova

¹Belgorod State University, 85, Pobedy St., Belgorod, 308015, Russia

*Corresponding author: Vladimir V. Gureev, Belgorod State University, 85, Pobedy St., Belgorod, 308015, Russia; Email: gureev@bsu.edu.ru

Received/Recibido: 06/28/2020 Accepted/Aceptado: 07/15/2020 Published/Publicado: 09/07/2020 DOI: 10.5281/zenodo.4265179

Abstract

Objective. Investigate the endothelioprotective properties of short-chain derivatives of erythropoietin in experimental preeclampsia.

Methodology. The experiment was performed in 100 white female Wistar rats weighing 250-300 g. L-NAME was administered intraperitoneally (25 mg/kg/day) from 14 to 20 days of pregnancy. The studied peptides (50 μ g/kg) were administered intraperitoneally once a day from 10 to 20 days of pregnancy. On the 21st day of pregnancy, functional tests and laboratory tests were performed.

Results. Rat pretreatment with the studied peptides reverted pathological changes in experimental ADMA-like preeclampsia. The greatest effect was observed with the peptide with the laboratory code P- α B1. A significant decrease in systolic and diastolic blood pressure was observed, improved microcirculation in the placenta, restoration of the endothelium NO-synthesizing function, and a decrease in proteinuria.

Conclusion. The results of the study are promising for the use of short-chain derivatives of erythropoietin simulating its α -helix B for the correction of morpho-functional changes in experimental preeclampsia and substantiate the desirability of further research in this direction.

Keywords: erythropoietin, preeclampsia, endothelial dysfunction, rats, proteinuria, microcirculation.

Resumen

Objetivo. Investigar las propiedades endotelio protectoras de los derivados de la eritropoyetina de cadena corta en la preeclampsia experimental.

Metodología. El experimento se realizó en 100 ratas Wistar hembra blancas con un peso de 250-300 g. Se administró L-NAME por vía intraperitoneal (25 mg/kg/día) a los 14 a 20 días de embarazo. Los péptidos estudiados (50 μ g/kg) se administraron intraperitonealmente, una vez al día desde el día 10 al 20 de embarazo. El día 21 del embarazo, se realizaron pruebas funcionales y pruebas de laboratorio.

Resultados. El pretratamiento de las ratas con los péptidos estudiados revirtió los cambios patológicos en la preeclampsia experimental similar a ADMA. El mayor efecto se observó con el péptido con el código de laboratorio P- α B1. Se observó una disminución significativa en la presión arterial sistólica y diastólica, una mejor microcirculación en la placenta, la restauración de la función sintetizadora de NO del endotelio y una disminución de la proteinuria.

Conclusión. Los resultados del estudio son prometedores para el uso de los derivados de la eritropoyetina de cadena corta que simulan su α -hélice B para la corrección de los cambios morfo-funcionales en la preeclampsia experimental y corroboran la conveniencia de futuras investigaciones en esta dirección.

Palabras clave: eritropoyetina, preeclampsia, disfunción endotelial, ratas, proteinuria, microcirculación.

Introduction

In search of new drugs for the treatment and prevention of diseases, is an urgent task of modern pharmacology¹⁻⁵. One of these areas is obtaining drugs for the treatment and prevention of preeclampsia (PE)⁶⁻⁸. In developed countries, it accounts for about 16-18% of maternal deaths and up to 40% of fetal and newborn deaths⁹. In women with preeclampsia, the complication rate can reach 22%¹⁰. Preeclampsia (PE) is a complex disease, exclusive to human pregnancy, being the main cause of fetal and maternal morbidity and mortality, preterm birth, intrauterine growth retardation, and perinatal mortality. It is characterized by new-onset hypertension and proteinuria, which usually arises after 20 weeks of gestation, more frequently in the third trimester and reverses in the postpartum period¹¹.

A large number of studies have been conducted around the world to increase the effectiveness of the treatment and prevention of this disease. Moreover, preeclampsia is increasingly seen in endothelial dysfunction¹². One of the mechanisms for the development of endothelial dysfunction in preeclampsia is "oxidative stress" as a result of the depletion of the antioxidant system in conditions of tissue ischemia¹³. Developing against this background, endothelial dysfunction leads to impaired microcirculation and tissue hypoxia, and as a result, to the development of multiple organ disorders that make up the clinical manifestations of preeclampsia^{14,32}. One of the leading pathophysiological factors in reducing the activity of endothelial NO-synthase (e-NOS) and the development of preeclampsia is placental ischemia. An increase in the activity of NO-synthase can be achieved by reducing the ischemic phenomena of the placenta.

The evidence indicates a positive effects of recombinant erythropoietin and its derivatives in experimental preeclampsia. Among them are the cytoprotective action due to the activation of the heterodimeric receptor for erythropoietin. A simpler and relatively cheaper way may be the use of short-chain derivatives of erythropoietin that mimic its α -helix B¹⁵. Such derivatives are polypeptides that model the active center of erythropoietin binding to the receptor. With this in mind, these polypeptides retain the ability to bind to the heterodimeric receptor, but concerning erythropoietin, they will have greater penetration into tissues due to their lower mass.

Based on the evidence it could be possible that these peptides could be effective in pregnant women with impaired growth and placenta formation in early pregnancy with outcome in placental ischemia and impaired endothelial function. In support of this assumption, we found that the basic 11-amino acid peptide P- α B (QEQLERALNSS), which mimics the structure of erythropoietin α -helix B has a pronounced endothelial-protective and potentially atheroprotective effect due to its ability to prevent the death of endothelial cells, however it shows prothrombotic activity in rats, suggesting the requirement for necessitates further modifications of this molecule¹⁶. We look forward as a prospect in the modification of P- α B by attaching peptide motifs with antiplatelet activity. In the framework of this study, the pharmacological activity obtained by modifying

the initial peptide with the introduction of the RGD motif (Arg-Gly-Asp) into the structure was studied. In addition, it was investigated the endothelioprotective properties of short-chain derivatives of erythropoietin in experimental preeclampsia induced by the inhibition of nitric oxide (NO) synthesis with N-nitro-L-arginine-methyl ether (L-NAME).

Material and Methods

The experimental study was conducted at the Research Institute of Pharmacology of Living Systems of Belgorod State National Research University. The study was performed in compliance with the requirements of General Requirements for the Competence of Testing and Calibration Laboratories 17025-2009, GOST R ISO 5725-2002 and the Rules of Laboratory Practice, approved by Order of the Ministry of Healthcare and Social Development of the Russian Federation dated August 23rd, 2010 № 708n, in compliance with the European Convention for the Protection of Vertebrates Used for Experiments or Other Scientific Purposes CETS No. 170. All the experiments were approved by the Ethical Committee of Belgorod National Research University.

The experiment was performed in 120 female white Wistar rats weighing 250-300 g. For the formation of groups of pregnant animals with predetermined periods that were kept separately, females (3 animals) were planted males (2 animals) for 24 hours. Then the animals were seated and on the 10th day in the condition of ether sleep, the presence of pregnancy was determined by palpation. In our experiments, pregnancy occurred in 30-40%. ADMA-like agent - a non-selective NO-synthase blocker N-nitro-L-arginine-methyl ether (L-NAME) was administered intraperitoneally at a dose of 25 mg/kg/day for seven days (14-20 days of pregnancy)^{15,17}.

The studied innovative peptides that mimic the erythropoietin α -helix B were administered intraperitoneally at a dose of 50 μ g/kg once a day for 10 days (10-20 days of pregnancy). Intact animals were injected intraperitoneally with saline at a dose of 10 ml/kg for 10 days.

In view of the goal, the following groups of animals were formed:

1. Control (0.9% NaCl).
2. L-NAME 25 mg/kg
3. L-NAME + P- α B (QEQLERALNSS) 50 μ g/kg
4. L-NAME + P- α B1 (RGDQEQLERALNSS) 50 μ g/kg
5. L-NAME + P- α B2 (QEQLERALNSSRGD) 50 μ g/kg

On the 21st day of pregnancy, the laboratory animal was anesthetized by intraperitoneal injection of chloral hydrate at a dose of 300 mg/kg body weight, after which functional tests were performed¹⁷⁻²⁰.

The degree of endothelial dysfunction in experimental animals was evaluated by the ratio of endothelium-dependent

vasodilation and endothelium-independent vasodilation with subsequent calculation of the coefficient of endothelial dysfunction (QED)²¹⁻²⁵. The level of NO metabolites (i.e., the total concentration of nitrates and nitrites, NOx) was determined by the colorimetric method according to the development of color in the diazotization reaction of sulfonamide nitrite, which is part of the Griess reagent.

To obtain data on the state of microcirculation in the placenta on the 21st day of pregnancy under anesthesia at 4 points, the microcirculation level was measured at a distance of 1 mm from the edge of the placental disc. To obtain data on the state of microcirculation in the placenta, Biopacsystems equipment was used: MP100 polygraph with laser Doppler flowmetry module (LDF) LDF100C and invasive needle probe TSD144, which was mounted directly on the projection of the placental disc. The LDF results were recorded and processed using the AcqKnowledge software version 3.8.1. Microcirculation values were expressed in perfusion units (PUn)^{21,26,27}.

The biochemical markers of endothelial dysfunction were indicators of the concentration of stable nitric oxide metabolites (Total NOx). The level of NO metabolites (i.e., the total concentration of nitrates and nitrites, NOx) was determined by the colorimetric method according to the development of color in the diazotization reaction of sulfonamide nitrite, which is part of the Griess reagent.

Descriptive statistics were applied to all data: the data were analyzed for normal distribution. The type of distribution was determined by the Shapiro-Wilk criterion. In the case of a normal distribution, the mean value (M) and the standard error of the mean (m) were calculated. When analyzing intergroup differences, the Student t-test or Mann-Whitney U-test was used, depending on the type of distribution. A values of $p < 0.05$ was considered significant.

Results and Discussion

After administration of L-NAME, a significant increase in blood pressure occurred in pregnant rats: systolic blood pressure (SBP) was 194.8 ± 7.88 mmHg, disdtolic blood pressure DBP 149.8 ± 4.73 mm Hg, while in intact animals; systolic and diastolic blood pressure values were 132.3 ± 3.46 and 92.40 ± 3.87 mm Hg, respectively. In pregnant rats treated with L-NAME, the coefficient of endothelial dysfunction increased from 1.20 ± 0.07 to 3.17 ± 0.22 , and the rate of microcirculation in the placenta decreased from 465.9 ± 28.79 PUn to 211.8 ± 6.03 PUn ($p < 0.05$).

Administration of peptide (P- α B) (50 μ g/kg), mimiking the α -helix B of erythropoietin, during the 10 to 20 day of pregnancy, there was a significant ($p < 0.05$) decrease in systolic and diastolic blood pressure to 142.8 ± 1.98 and 90.40 ± 5.21 mm Hg, compared with L-NAME pregnant rats (Table 1). Meanwhile, the coefficient of endothelial dysfunction decreased to 2.0 ± 0.06 , and the microcirculation index increased to 343.2 ± 5.98 PUn ($p < 0.05$).

Table 1. The effect of innovative peptides that mimic the α -helix B of erythropoietin on blood pressure, CED and microcirculation in the placenta with ADMA-like preeclampsia

	SBP, mm hg	DBP, mm hg	CED, cond. un.	Microcirculation, PUn
Control saline	$132.3 \pm 3.46^*$	$92.4 \pm 3.87^*$	$1.20 \pm 0.07^*$	$465.9 \pm 28.79^*$
L-NAME	$194.8 \pm 7.88^\#$	$149.8 \pm 4.73^\#$	$3.17 \pm 0.22^\#$	$211.8 \pm 6.03^\#$
P- α B (50 μ g/kg)	$142.8 \pm 1.98^{*\#}$	$90.4 \pm 5.21^*$	$2.0 \pm 0.06^{*\#}$	$343.2 \pm 5.98^{*\#}$
P- α B1 (50 μ g/kg)	$143.1 \pm 5.18^*$	$100.6 \pm 3.80^*$	$1.80 \pm 0.15^{*\#}$	$378.1 \pm 9.45^{*\#}$
P- α B2 (50 μ g/kg)	$172.8 \pm 5.06^{*\#}$	$135.2 \pm 3.54^{*\#}$	$2.25 \pm 0.16^{*\#}$	$351.2 \pm 10.04^{*\#}$


SBP, DBP - systolic and diastolic blood pressure (mmHg) CED - coefficient of endothelial dysfunction (cond. un.); PUn - perfusion units; $^\#p < 0.05$ compared with a group of intact animals; $*p < 0.05$ compared with the L-NAME group.

Administration of the studied innovative peptide P- α B1, that mimics the α -helix B of erythropoietin, presented a greatest endothelioprotective effect. The coefficient of endothelial dysfunction decreased to 1.80 ± 0.15 , and microcirculation rose to 378.1 ± 9.45 PUn, however the values did not reach basal levels (Table 1). It should be noted that peptides P- α B1 administration reduced blood pressure values to those control animals.

Administration of the peptide P- α B2, also reverted, in less extend, the hemodynamic parameters in experimental preeclampsia induced by L-NAME (Table 1).

The study of the NO-synthesizing function of the endothelium was carried out based on the determination of nitrite - NOx ions in blood plasma. During experimental preeclampsia there was a significant decrease in the content of final plasma NOx metabolites (Figure 1). Intraperitoneally administration of P- α B during the day 10 to 20 of pregnancy, reverted partially plasma NOx metabolites levles ($p < 0.05$) to 1.59 ± 0.05 μ mol/dL. In addition, this efect was also observed after the administration of P- α B1 (1.83 ± 0.02 μ mol/dL) and P- α B2.

Figure 1. The effect of innovative peptides that mimic the erythropoietin α -helix B on the content of final NOx metabolites in blood plasma with ADMA-like pre-eclampsia $^\#p < 0.05$ in comparison with a group of intact animals; $*p < 0.05$ in comparison with the L-NAME group.



In response to placental ischemia, a large number of humoral factors are released that provoke the development of endothelial dysfunction^{28,30,33}. From the foregoing, it was logical to assume that pharmacological agents with anti-ischemic and cytoprotective effects can indirectly reduce endothelial dysfunction with preeclampsia. However, it should be noted that preeclampsia often develops and is more severe in women with previous endothelial dysfunction. Therefore, for our experiment, we chose an ADMA-like model, which also has an ischemic component³¹. Activation of the heterodimeric receptor to erythropoietin increases tissue resistance to ischemia. This leads to a decrease in the formation of humoral factors causing endothelial dysfunction.

Conclusion

Administration of short-chain derivatives of erythropoietin simulating its α -helix B in rats with experimental preeclampsia induced by NO synthesis inhibition, showed a reversion in the parameters evaluated, being P- α B1 with the amino acid sequence: RGDQEQLERALNSS the most promising. The results suggest that is required further research on the search for drugs for the treatment and prevention of preeclampsia among erythropoietin derivatives.

ACKNOWLEDGEMENTS

The study was supported by the Ministry of Science and Higher Education of the Russian Federation (subsidy agreement No. 05.605.21.0191, the unique identifier of the agreement is RFMEFI60519X0191).

References

1. Soldatov, V.O., Shmykova, E.A., Pershina, M.A., Ksenofontov, A.O., Zamitsky, Y.M., Kulikov, A.L., Peresyphina, A.A., Dovgan, A.P., Belousova, Y.V., 2018. Imidazoline receptors agonists: possible mechanisms of endothelioprotection. *Res Results Pharmacol*, 4(2):11-18. <https://doi.org/10.3897/rrpharmacology.4.27221>
2. Korokina, L.V., Zhernakova, N.I., Korokin, M.V., Pokopejk, O.N., 2018. Principles of pharmacological correction of pulmonary arterial hypertension. *Research Results in Pharmacology*, 4(2):59-76. <https://doi.org/10.3897/rrpharmacology.4.27732>
3. Bushmina, O.N., Loktionov, A.L., Dolgareva, S.A., et al., 2018. Pharmacological correction of metabolic disturbances in experimental acute pancreatitis on the background of chronic alcohol intoxication. *Research Results in Biomedicine*, 4(4): 35-51 (In Russian) DOI: 10.18413/2313-8955-2018-4-4-0-5
4. Skachilova, S.Ya., Kotelnikova, A.S., Timokhina, A.S., et al., 2018. Evaluation of antihypoxic activity of ethylmethylhydroxypyridine succinate in vitro experiments. *Research Results in Biomedicine*, 4(3), 70-75 (In Russian). DOI: 10.18413/2313-8955-2018-4-3-0-7
5. Solin, A.V., Lyashev, Y.D., Tsygan, N.V., 2019. Hepatoprotective effect of opioid peptides in stress. *Res Results Pharmacol*, 5(1):77-96. <https://doi.org/10.3897/rrpharmacology.5.34472>
6. Severinova, O.V., Lokteva, T.I., Gureev, V.V., Zhernakova, N.I., Osipova, O.A., Dolzhikov, A.A., Pokrovskaya, T.G. 2019. The effect of arginase II selective inhibitors on the functional parameters

of experimental animals in ADMA-like preeclampsia. *Journal of International Pharmaceutical Research*, 46(4):272–275.

7. Stupakova, E.G., Lazareva, G.A., Gureev, V.V., 2018. Correction of morphofunctional disturbances arising when modeling Preeclampsia with resveratrol and nicorandil. *Research Results in Pharmacology*, 4(1):59-71. <https://doi.org/10.3897/rrpharmacology.4.25528>
8. Lokteva, T.I., Rozhkov, I.S., Gureev, V.V., Gureeva, A.V., Zatulokina M.A., Avdeeva, E.V., Zhilinkova, L.A., Prohoda, E.E., Yarceva, E.O., 2020. Correction of morphofunctional disorders of the cardiovascular system with asialized erythropoietin and arginase II selective inhibitors KUD 974 and KUD 259 in experimental preeclampsia. *Research Results in Pharmacology*, 6(1):29-40. <https://doi.org/10.3897/rrpharmacology.6.50851>
9. Pankiewicz, K., Szczerba, E., Maciejewski, T., Fijałkowska, A. 2019. Non-obstetric complications in preeclampsia. *Prz Menopauzalny*, 18(2): 99-109.
10. Un Nisa, S., Shaikh, A.A., Kumar, R., 2019. Maternal and Fetal Outcomes of Pregnancy-related Hypertensive Disorders in a Tertiary Care Hospital in Sukkur, Pakistan. *Cureus*, Aug 28;11(8):e5507. doi: 10.7759/cureus.5507.
11. Shaheen, G., Jahan, S., Ain Q.U., Ullah, A., Afsar, T., Almajwal, A., Alam, I., Razak, S., 2019. Placental endothelial nitric oxide synthase expression and role of oxidative stress in susceptibility to preeclampsia in Pakistani women. *Mol Genet Genomic Med*, Nov 8:e1019. doi: 10.1002/mgg3.1019.
12. Vodneva, D.N., 2013. Akusherstvo i ginekologiya. *Obstetrics and gynecology*, 11: 9-12. (in Russian)
13. Krasnyj, A.M., Kan, N.E., Tyutyunnik, V.L. et al., 2016. Akusherstvo i ginekologiya. *Obstetrics and gynecology*, 5: 90-95. (in Russian)
14. Sidorova, I.S., Nikitina, N.A., Unyanan A.L. et al., 2013. *Rossijskij vestnik akushera-ginekologa*. *Russian Bulletin of the obstetrician-gynecologist*, 13(3): 4-8. (in Russian)
15. Pokrovskii, M.V., Yurakova, A.V., Gureev, V.V., Golubev, I.V., Korokin, M.V., Gudyrev, O.S., Pokrovskaja, T.G., 2019. Integrated evaluation of the endothelioprotective activity of an innovative peptide simulating the alpha-helix of b-erythropoethin in L-NAME-induced nitrogen oxide deficiency at the late gestation period. *Journal of Critical Reviews*, 6: 180-184.
16. Korokin, M.V., Soldatov, V.O., Tietze, A.A., Golubev, M.V., Belykh, A.E., Kubekina, M.V., Puchenkova, O.A., Denisyuk, T.A., Gureyev, V.V., Pokrovskaya, T.G., Gudyrev, O.S., Zhuchenko, M.A., Zatulokina, M.A., Pokrovskiy, M.V., 2019. 11-amino acid peptide imitating the structure of erythropoietin α -helix b improves endothelial function but stimulates thrombosis in rats. *Pharmacy & Pharmacology*, 7(6):312-320. (in Russian) <https://doi.org/10.19163/2307-9266-2019-7-6-312-320>
17. Severinova, O.V., Gureev, V.V., Zhilinkova, L.A., Lazareva, G.A., Gureeva, A.V., Lazareva, S.S., 2019. Study of the effect of selective inhibitor of Arginase II KUD 975 and of low doses of Acetylsalicylic acid on the functional parameters of the cardiovascular system in experimental preeclampsia. *Research Results in Pharmacology*, 5(4): 47–56. <https://doi.org/10.3897/rrpharmacology.5.47654>
18. Antsiferova, O.E., Gureev, V.V., Gureeva, A.V., Avdeyeva, E.V., Mikhaylova, Y.A., Kuzmin, D.B., 2020. Comprehensive assessment of using micronised purified flavonoid fraction in the correction of disorders associated with ADMA-like preeclampsia in experiment. *Research Results in Biomedicine*, 6(1):78-93. (In Russian) DOI: 10.18413/2658-6533-2020-6-1-0-7.
19. Severinova, O. V., Lazareva, G.A., Zhilinkova, L.A., Gureeva, A.V., 2020. Pharmacological effects of the combined administration of

- a small dose of Acetylsalicylic acid and methyl dopa in ADMA-like preeclampsia. *Research Results in Biomedicine*, 6(1): 94-106. (In Russian) DOI: 10.18413/2658-6533-2020-6-1-0-8.
20. Korokin, M., Gudyrev, O., Gureev, V., Korokina, L., Peresyphkina, A., Pokrovskaia, T., Lazareva, G., Soldatov, V., Zatulokina, M., Pokrovskii, M., 2020. Studies to Elucidate the Effects of Furostanol Glycosides from *Dioscorea deltoidea* Cell Culture in a Rat Model of Endothelial Dysfunction. *Molecules*, 25(1):169. <https://doi.org/10.3390/molecules25010169>
 21. Gureev, V.V., Pokrovskii, M.V., Korokin, M.V., Gudyrev, O.S., Philippova, O.V., Dolzhikov, A.A., Lazareva, G.A., 2015. Correction of ADMA-induced preeclampsia with use of tetrahydrobiopterin and selective inhibitor of arginase II ZB49-0010. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, 6(5):1538–1541. <https://doi.org/10.18413/2313-8955-2015-1-4-66-68>
 22. Korokin, M.V., Pokrovskii, M.V., Gudyrev, O.S., Korokina, L.V., Pokrovskaia, T.G., Lazarev, A.I., Philippenko, N.G., Gureev, V.V., 2015. Pharmacological correction of endothelial dysfunction in rats using e-NOS cofactors. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, 6(5):1548–1552.
 23. Pokrovskii, M.V., Kochkarov, V.I., Pokrovskaya, T.G., Artyushkova, E.B., Pashin, E.N., Danilenko, L.M., Zhavbert, E.S., 2009. Comparative study of potential endothelioprotectors and impaza in modeled nitric oxide deficiency. *Bulletin of Experimental Biology and Medicine*, 148(3): 514-517. doi:10.1007/s10517-010-0751-4
 24. Denysiuk, T.A., Sernov, L.N., Lutsenko, V.D., Shiryayev, O.U., Shaposhnikov, A.A., Pokrovsky, M.V., Gudyrev, O.S., 2015. Cardioprotective effects of HMG-co-A inhibitors: Role of the mechanisms of preconditioning. *Research Journal of Medical Sciences*, 9(4): 245-248. doi:10.3923/rjmsci.2015.245.248
 25. Pokrovskaya, T.G., Korokin, M.V., Gudyrev, O.S., Sernov, L.N., Osipova, O.A., Chadieva, T.A., Dovgan, A.P., 2016. Combined pharmacological correction of the metabolic pathways of L-arginine/ nohypoestrogenemia in the simulation of deficiency of nitric oxide. *International Journal of Pharmacy and Technology*, 8(3): 15175-15181
 26. Stupakova, E.G., Lazareva, G.A., Gureev, V.V., Dolzhikova, I.N., Zhilinkova, L.A., Gureeva, A.V., 2019. L-NAME-induced preeclampsia: correction of functional disorders of the hemostasis system with Resveratrol and Nicorandil. *Research Results in Pharmacology*, 5(2): 1-12. <https://doi.org/10.3897/rrpharmacology.5.35316>
 27. Khadieva, T.A., Pokrovskaya, T.G., Belousova, Y.V., 2019. Pharmacological correction of endothelial dysfunction using ademetionin and taurine. *Research Results in Pharmacology*, 5(2): 13-21. <https://doi.org/10.3897/rrpharmacology.5.32730>
 28. Ducray, J.F., Naicker, T., Moodley, J., 2011. Pilot study of comparative placental morphometry in preeclamptic and normotensive pregnancies suggests possible maladaptations of the fetal component of the placenta. *Eur J Obst Gynecol Reprod Biol*, 156(1): 29-34.
 29. Fang, M.R., Li, J.C., 2005. Evaluation of the efficacy of ligustrazine collaborated with magnesium sulfate in the treatment of pregnancy-induced hypertension in rats. *Shi Yan Sheng Wu Xue Bao*, 38(1):45-53.
 30. Sheppard, S.J., Khalil, R.A., 2010. Risk Factors and Mediators of the Vascular Dysfunction Associated with Hypertension in Pregnancy. *Cardiovascular & Hematological Disorders-Drug Targets*, 10(1):33-52.
 31. Ruiqiong, M.A., Sun Minna, Yang, Zi., 2010. Effects of preeclampsia-like symptoms at early gestational stage on feto-placental outcomes in a mouse model. *Chinese Med J*, 123(6):707-712.
 32. Savenkova, I., Didukh, M., Khazratova, N., & Snyadanko, I. (2019). Psychosomatic unity of human from the position of chronopsychology on the example of ischemic disorders and heart diseases. *Electronic J General Med*, 16(6).
 33. Rashad, A. M., Heeba, G. H., & Hamad, S. H. (2019). Age-dependent Role of Cilostazol on Cold Restraint Stressinduced Gastric Ulceration in Female Rats. *J Clin Experim Investigations/ Klinik ve Deneysel Arastirmalar Dergisi*, 10(3).